ASXL1
Basic information
Region (hg38): 20:32358330-32439319
Links
Phenotypes
GenCC
Source:
- Bohring-Opitz syndrome (Definitive), mode of inheritance: AD
- Bohring-Opitz syndrome (Definitive), mode of inheritance: AD
- Bohring-Opitz syndrome (Strong), mode of inheritance: AD
- Bohring-Opitz syndrome (Strong), mode of inheritance: AD
- Bohring-Opitz syndrome (Strong), mode of inheritance: AD
- Bohring-Opitz syndrome (Supportive), mode of inheritance: AD
- Bohring-Opitz syndrome (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Bohring-Opitz syndrome | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Dermatologic; Musculoskeletal; Neurologic | 21706002; 22419483 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (46 variants)
- Bohring-Opitz syndrome (27 variants)
- Inborn genetic diseases (8 variants)
- ASXL1-related disorder (2 variants)
- Myelodysplastic syndrome (2 variants)
- Deficiency of iodide peroxidase (1 variants)
- 10 conditions (1 variants)
- dystrophia;Developmental delay (1 variants)
- Spinocerebellar ataxia 45 (1 variants)
- Myelodysplasia (1 variants)
- Autosomal recessive limb-girdle muscular dystrophy (1 variants)
- Rubinstein Taybi like syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ASXL1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 194 | 14 | 212 | |||
missense | 364 | 90 | 38 | 493 | ||
nonsense | 30 | 37 | ||||
start loss | 1 | |||||
frameshift | 44 | 16 | 63 | |||
inframe indel | 10 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 6 | 16 | 22 | |||
non coding | 38 | 17 | 60 | |||
Total | 76 | 25 | 385 | 324 | 69 |
Highest pathogenic variant AF is 0.0000263
Variants in ASXL1
This is a list of pathogenic ClinVar variants found in the ASXL1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
20-32358494-C-T | Likely benign (Nov 25, 2018) | |||
20-32358685-A-ACCG | Bohring-Opitz syndrome | Conflicting classifications of pathogenicity (Jul 01, 2023) | ||
20-32358753-TGCC-T | ASXL1-related disorder | Likely benign (Dec 21, 2023) | ||
20-32358772-A-G | Benign (Dec 30, 2019) | |||
20-32358776-A-C | Uncertain significance (Aug 10, 2020) | |||
20-32358788-CAGA-C | Benign/Likely benign (Jul 01, 2024) | |||
20-32358793-G-A | Likely benign (Aug 04, 2023) | |||
20-32358793-G-C | Inborn genetic diseases | Uncertain significance (Apr 24, 2024) | ||
20-32358804-A-G | Inborn genetic diseases | Uncertain significance (Jan 18, 2022) | ||
20-32358811-G-A | Likely benign (Jul 19, 2023) | |||
20-32358816-C-T | Uncertain significance (Oct 27, 2022) | |||
20-32358823-C-T | Likely benign (Mar 26, 2022) | |||
20-32358828-G-T | Uncertain significance (Dec 03, 2021) | |||
20-32358829-C-T | Likely benign (Dec 17, 2023) | |||
20-32358841-G-T | Likely benign (Aug 04, 2023) | |||
20-32358843-C-T | Likely benign (Dec 14, 2023) | |||
20-32358849-AGGGGGGCTCCGTGGGGCCCGGGGTGG-A | Likely benign (May 12, 2022) | |||
20-32358849-A-AG | Benign (Dec 13, 2023) | |||
20-32358851-G-A | Bohring-Opitz syndrome;Myelodysplastic syndrome • Bohring-Opitz syndrome | Benign/Likely benign (Jan 29, 2024) | ||
20-32358884-C-T | Benign (Sep 23, 2019) | |||
20-32359043-G-GC | Likely benign (Aug 21, 2019) | |||
20-32359302-A-C | Likely benign (Jul 01, 2024) | |||
20-32359310-G-T | ASXL1-related disorder | Uncertain significance (Oct 03, 2023) | ||
20-32366367-C-T | Likely benign (Oct 18, 2023) | |||
20-32366372-A-G | Likely benign (Aug 12, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ASXL1 | protein_coding | protein_coding | ENST00000375687 | 13 | 80968 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.25e-14 | 0.995 | 125652 | 0 | 96 | 125748 | 0.000382 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.636 | 791 | 843 | 0.938 | 0.0000501 | 10006 |
Missense in Polyphen | 230 | 297.05 | 0.77429 | 3532 | ||
Synonymous | -0.416 | 349 | 339 | 1.03 | 0.0000212 | 3221 |
Loss of Function | 2.77 | 31 | 52.7 | 0.589 | 0.00000322 | 616 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000420 | 0.000420 |
Ashkenazi Jewish | 0.000595 | 0.000595 |
East Asian | 0.000229 | 0.000217 |
Finnish | 0.000185 | 0.000185 |
European (Non-Finnish) | 0.000601 | 0.000589 |
Middle Eastern | 0.000229 | 0.000217 |
South Asian | 0.000196 | 0.000131 |
Other | 0.000165 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG). Acts as coactivator of RARA and RXRA through association with NCOA1. Acts as corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1). {ECO:0000250, ECO:0000269|PubMed:16606617, ECO:0000269|PubMed:20436459}.;
- Disease
- DISEASE: Bohring-Opitz syndrome (BOPS) [MIM:605039]: A syndrome characterized by severe intrauterine growth retardation, poor feeding, profound mental retardation, trigonocephaly, prominent metopic suture, exophthalmos, nevus flammeus of the face, upslanting palpebral fissures, hirsutism, and flexion of the elbows and wrists with deviation of the wrists and metacarpophalangeal joints. {ECO:0000269|PubMed:21706002}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myelodysplastic syndrome (MDS) [MIM:614286]: A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). {ECO:0000269|PubMed:19388938, ECO:0000269|PubMed:20182461}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Post-translational protein modification;Metabolism of proteins;UCH proteinases;Deubiquitination
(Consensus)
Recessive Scores
- pRec
- 0.0787
Intolerance Scores
- loftool
- 0.955
- rvis_EVS
- 0.17
- rvis_percentile_EVS
- 65.77
Haploinsufficiency Scores
- pHI
- 0.147
- hipred
- N
- hipred_score
- 0.214
- ghis
- 0.523
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.756
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Asxl1
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- cell morphogenesis;heart morphogenesis;transcription, DNA-templated;animal organ morphogenesis;protein deubiquitination;hemopoiesis;response to retinoic acid;negative regulation of peroxisome proliferator activated receptor signaling pathway;monoubiquitinated histone H2A deubiquitination;negative regulation of fat cell differentiation;positive regulation of transcription by RNA polymerase II;positive regulation of retinoic acid receptor signaling pathway;thymus development;bone marrow development;homeostasis of number of cells;lung saccule development
- Cellular component
- nuclear chromatin;nucleus;nucleoplasm;PR-DUB complex
- Molecular function
- DNA binding;chromatin binding;transcription coactivator activity;protein binding;retinoic acid receptor binding;peroxisome proliferator activated receptor binding;metal ion binding